Obstetric outcomes of the different groups
| Group A n=72 | Group B n=72 | Group C n=73 | A vs B | A vs C | B vs C | |
| Primary outcomes | ||||||
| Thromboembolism | ||||||
| Antepartum | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| 6 weeks post partum | 3 (4.2) | 1 (1.4) | 0 (0.0) | 0.104 | 0.012 | 0.495 |
| 3 months post partum | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Anti-factor Xa level | ||||||
| Right after delivery | 0.23±0.08 | 0.25±0.09 | 0.32±0.12 | 0.179 | 0.019 | 0.027 |
| 6 weeks post partum | 0.28±0.11 | 0.29±0.09 | 0.45±0.13 | 0.358 | 0.011 | 0.013 |
| 3 months post partum | 0.49±0.11 | 0.47±0.13 | 0.55±0.15 | 0.223 | 0.297 | 0.314 |
| Thrombophlebitis | 9 (12.5) | 4 (5.6) | 5 (6.8) | 0.015 | 0.013 | 0.445 |
| Secondary outcomes | ||||||
| Spontaneous abortion | 0 (0.0) | 2 (2.8) | 0 (0.0) | 0.514 | – | 0.496 |
| Intrauterine fetal death (>23 weeks) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Gestational age at delivery, weeks | ||||||
| Delivery <37 weeks | 7 (9.7) | 10 (13.9) | 8 (11.0) | 0.281 | 0.466 | 0.356 |
| Delivery >37 weeks | 65 (90.3) | 60 (83.3) | 65 (89.0) | 0.304 | 0.389 | 0.355 |
| Placental abruption | 4 (5.6) | 1 (1.4) | 1 (1.4) | 0.210 | 0.307 | 0.769 |
| Pre-eclampsia | 7 (9.7) | 10 (13.9) | 5 (6.8) | 0.580 | 0.393 | 0.282 |
| Mild | 5 (6.9) | 6 (8.3) | 3 (4.1) | 0.368 | 0.375 | 0.276 |
| Late severe | 2 (2.8) | 4 (5.6) | 2 (2.7) | 0.464 | 0.625 | 0.374 |
| Early severe (<34 weeks) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Postpartum hemorrhage | 5 (6.9) | 1 (1.4) | 0 (0.0) | 0.014 | 0.006 | 0.495 |
| Within 24 hours | 3 (4.2) | 1 (1.4) | 0 (0.0) | 0.176 | 0.021 | 0.406 |
| Within 6 weeks | 2 (2.8) | 0 (0.0) | 0 (0.0) | 0.532 | 0.469 | – |
| SEH | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0.773 | 0.635 | – |
| Mode of delivery | ||||||
| Vaginal | 55 (76.5) | 51 (70.8) | 59 (81.2) | 0.611 | 0.498 | 0.680 |
| Cesarean | 17 (23.6) | 19 (26.4) | 14 (19.2) | 0.473 | 0.321 | 0.304 |
| Neonatal birth weight, g | 3017.5±459 | 2976.4±672 | 3135.4±327 | 0.320 | 0.306 | 0.403 |
| Neonatal birth weight <2500 g | 9 (12.5) | 11 (15.3) | 7 (9.6) | 0.495 | 0.410 | 0.372 |
| Dalteparin side effects | ||||||
| Bleeding | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Thrombocytopenia | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Thrombotic episodes | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
| Skin allergy | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – | – |
Data are expressed as n (%), except for neonatal birth weight which is expressed as mean±SD.
Data in bold indicates significant difference.
Group A: fixed dose group; group B: weight group; group C: anti-FXa+weight group.
FXa, factor Xa; SEH, obstetric spinal epidural hematoma.